# Federico Cappuzzo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/federico-cappuzzo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,371 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 89 |
| i10-index | 272 |
| Last Known Institution | Cancer Institute (WIA) |
| OpenAlex ID | https://openalex.org/A5001928949 |
| ORCID iD | https://orcid.org/0000-0002-6295-6767 |
| Works | 819 |

## Researcher papers

Showing 12 of 15.

- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer/)
- [Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial](https://scholariq.org/papers/atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced/)
- [Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study](https://scholariq.org/papers/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant/)
- [Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort](https://scholariq.org/papers/lung-cancer-patients-with-her2-mutations-treated-with-chemotherapy-and-her2/)
- [IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain](https://scholariq.org/papers/impower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Cancer Institute (WIA)](https://scholariq.org/institutions/cancer-institute-wia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.